New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
13:56 EDTUTHRUnited Therapeutics price target raised to $75 from $65 at Argus
Argus increased its price target on United Therapeutics after the company reported higher than expected Q4 EPS. The firm continues to believe that the company will generate strong long-term growth, and it maintains a Buy rating.
News For UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
06:09 EDTUTHRUnited Therapeutics agrees to sell PPRV to AbbVie for $350M
United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use